Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Malihe HamidianFarzaneh ForoughiniaShirin HaghighatArmin AttarElham HaemPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Prophylactic ginseng supplementation may protect against doxorubicin-induced early cancer therapeutics-related cardiac dysfunction and early decline in left ventricular ejection fraction in breast cancer patients.
Keyphrases
- left ventricular
- double blind
- ejection fraction
- placebo controlled
- clinical trial
- aortic stenosis
- metastatic breast cancer
- high glucose
- diabetic rats
- oxidative stress
- phase ii
- drug delivery
- study protocol
- phase iii
- drug induced
- cancer therapy
- acute myocardial infarction
- papillary thyroid
- mitral valve
- squamous cell carcinoma
- randomized controlled trial
- hypertrophic cardiomyopathy
- small molecule
- transcatheter aortic valve replacement
- coronary artery disease
- atrial fibrillation
- aortic valve
- percutaneous coronary intervention